Nine innovative North Carolina life science companies are among the 22 chosen to pitch their technologies Nov. 6 and 7 at the 2013 Southeast BIO Investor & Partnering Forum in Richmond, Virginia.

The event, co-sponsored by the North Carolina Biotechnology Center at the iconic Jefferson Hotel, provides a showcase for some of the most promising bioscience and medical technology companies in the seven-state region, which also includes Alabama, Florida, Georgia, South Carolina, Tennessee, and Virginia.

The event gives executives of young companies picked by a selection committee of regional and national venture capitalists a chance to collect advice and investment.

One group of companies, dubbed MAIN/Stage presenting companies, have generally completed at least one round of institutional financing. They will make a 10-minute pitch to the full conference audience on Wednesday afternoon, November 6.

Companies in the EARLY/Stage event are seeking their first rounds of investment. They will participate in an individual private advisory session led by early-stage investors, entrepreneurs and experienced life science managers and service providers. Four EARLY/Stage companies will be selected to present to the full conference audience, with an overall “winner” announced at the closing lunch.

NC companies giving MAIN/Stage presentations are:

 

  • G1 Therapeutics of Chapel Hill, developing therapeutics to protect bone marrow from damage due to chemotherapy or radiation;
  • Pique Therapeutics, of Durham, developing therapeutic vaccines to treat cancer.

EARLY/Stage presenters from NC include:

  • Ardeal Pharma, of Brevard, developing treatments for dermal, pharmaceutical and cosmetic markets based on Stabilized Sulforaphane;
  • Camras Vision of Research Triangle Park, developing personalized care treatment for glaucoma patients to stop vision loss;
  • CanDiag of Charlotte, developing cancer screening technology for early detection of breast cancer;
  • Eboo Pharmaceuticals of Durham, developing pharmaceutical compounds for Parkinson’s disease and other indications;
  • NIRvana Sciences of RTP, developing novel dyes with ultra-narrow spectral properties;
  • Novocor Medical Systems of Raleigh, developing a rapid-chilling device to induce therapeutic hypothermia;
  • T3D Therapeutics of RTP, developing therapeutic to treat Alzheimer’s disease.

(C) NC Biotech Center